Effects of constant rate infusion of a fixed-dose combination of medetomidine and vatinoxan on cardiopulmonary function and gastrointestinal motility in standing Thoroughbred horses
Background: A fixed-dose medetomidine (MED) and vatinoxan (VTX) combination has recently become commercially available. Unlike atipamezole (ATIP), VTX is a peripherally selective α2-adrenoceptor antagonist. MED–VTX administered as a constant rate infusion (CRI) may offer safer sedation for horses by reducing MED-associated peripheral adverse effects.Aims/objectives: To evaluate the sedative, cardiopulmonary, and gastrointestinal effects of MED–VTX or MED–ATIP, administered as a CRI, compared with MED alone in Thoroughbred horses.Methods: In this blinded three-way crossover study, six healthy Thoroughbreds received an intravenous (IV) bolus of MED (7 μg/kg), followed by 60-min CRI at 5 μg/kg/h. Group M (gM) received MED alone, Group MV (gMV) received MED + VTX (140 μg/kg IV, CRI at 100 μg/kg/h), and Group MA (gMA) received MED + ATIP (140 μg/kg IV, CRI at 100 μg/kg/h). Sedation was assessed using descriptive scales, including head height, stimulus response score and ataxia score. Heart rate (HR), respiratory rate (RR), arrhythmias, and defecation were recorded.Results: Compared with the gM, sedation scales were maintained in the gMV but were significantly reduced in the gMA. The HR and RR did not differ significantly among groups. Second-degree atrioventricular block was observed in one, five, and six horses in the gMV, gM, and gMA, respectively. Defecation occurred in all horses in the gMV (median: 2.5 times, range: 1–4 times) but none in the other groups.Conclusion: Continuous MED–VTX administration provides effective sedation while reducing proarrhythmic risk and gastrointestinal inhibitory effects in Thoroughbred horses.